How pharmaceutical companies can use real-world data in clinical development?

With the ever-growing investment in real-world data (RWD), pharmaceutical firms are learning new ways of converting the data into meaningful real-world evidence (RWE). Although RWD has long been involved in health economics and commercial decision-making, its involvement in clinical development is growing at a rapid rate. With strategic use, RWE can shorten time frames, cut costs, enhance trial design, and ultimately raise the likelihood of technical and regulatory success.

Understanding the study population

Defining the appropriate study population is one of the largest problems in the field of clinical development strategy. Conventional trial planning usually uses historical research, little epidemiology data, or assumptions, which do not necessarily represent current treatment trends. Through the analysis of electronic health records (EHRs), claims databases and other real-world sources, companies can:

• Determine unmet needs in targeted groups of patients

  
  

• Know the patterns of disease progression across time

• Compare biomarkers between times

• Determine actual risk allocation in a target population

For example, in the cardiovascular field, longitudinal low-density lipoprotein cholesterol (LDL-C) patterns and major adverse cardiovascular events (MACE) can be analyzed to determine subgroups of patients who are at high risk. These understandings enable the sponsor to create trials that will be helpful to the patients and enhance the scientific rigor and regulatory positioning.

Trial design optimization using data insights

Trial design decisions, such as inclusion and exclusion criteria, directly affect feasibility, cost and success rates. Minor changes in the eligibility requirements may produce a massive impact on the cohort size and enrolment rate. Through federated EHR analytics solutions and massive patient repositories, pharmaceutical firms can:

• Calculate the population size of eligible patients in real time

• Replicate the effect of changing trial criteria

• Compare disease prevalence among geographic or demographic segments

• Check assumptions before finalizing protocol design

Rather than using the old epidemiology research only, sponsors can ask for new data to get up-to-date factual information. This can enable the clinical team to make quicker and more certain decisions and decrease the risk of developing too restrictive or impractical trials.

Supporting patient-centric trial design

One of the significant obstacles to clinical trial participation continues to be the burden placed on the patient. The high number of visits needed, the repetitive processes, and fixed schedules may not encourage enrolment and retention. In such cases, real world data may assist in quantifying the natural frequency of clinical visits (NFCV) in a therapeutic domain, in other words, the frequency with which patients engage with the healthcare system regularly. In comparison to this baseline, the proposed trial visit schedules, companies can:

• Defibrillate trial rate to natural patient behavior

• Reduce unnecessary visits

• Enhance compliance and retention

• Improve patient experience

Designing trials that capture care patterns, representing real-world care, is not only helpful in facilitating recruitment but also in enhancing the relevance of trial findings in everyday clinical practice.

Speeding up trial recruitment

The most frequent causes of clinical trials not keeping their schedule involve recruitment delays. A protocol might look workable on paper but fail to work when only a small number of eligible patients are found or recruited. Real-world data provides a more accurate method of assessing feasibility. Pharmaceutical firms can:

• Determine clinical locations that have high populations of eligible patients

• Assess actual patient numbers in advance of activation of the site

• Go beyond such conventional site networks

• Give priority to high-performing centers based on objective data

Rather than conducting a mass search of hundreds of locations, sponsors have an opportunity to implement targeted outreach using data-based feasibility studies. This enhances the efficiency of recruitment, decreases the costs and the time for the first patient in (FPI).

Real-world data is not simply a commercial or health economics instrument anymore, but it is becoming a key part of clinical innovation. It can be used wisely to refine study populations, design protocols, enhance patient experience, and accelerate recruitment. Firms that implement RWE within their clinical development framework gain more than operational efficiency; they create stronger evidence, less uncertainty and deliver meaningful therapies to patients sooner.